ORION-1 Impact of a 1- or 2-dose starting regimen of inclisiran, a - PowerPoint PPT Presentation

ORION-1 Impact of a 1- or 2-dose starting regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged LDL-C reductions over 1 year Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend, Peter Wijngaard, R Scott Wright, and John JP Kastelein On behalf of the ORION-1 investigators

2

Disclosures Research grants: • Amgen, Sanofi, Regeneron, MSD, Pfizer Consultancy: • Amgen, Sanofi, Regeneron, MSD, Pfizer, Astra Zeneca, Lilly, Medicines Company, Kowa, IONIS, Takeda, Novo Nordisk, Boehringer Ingelheim, Esperion, Cipla, Algorithm, Abbvie, Resverlogix, Cerenis 3

Background LDL-C variability common, associated with worse outcomes Six month percent change in LDL-C Increase in death, CV outcomes with among statin users from starting level 1 each 1 standard deviation of LDL-C variability 2 60 23% 40 17% 16% 20 11% 10% 0 -20 -40 Death Stroke Any Any CV MI coronary event -60 event 1. Ray KK et al. N Engl J Med 2017; 376:1430-1440 2. Bangalore S et al. JACC 2015; 65: 1539-1548 4

Background PCSK9 inhibition reduces LDL-C and ASCVD 1 PCSK9 monoclonal antibody treatment requires 12-26 injections per year 1 Adherence unlikely to show substantial improvement over statins 2 Limitations are most relevant in high risk patients needing lifelong therapy In the future can we do better? 1. Sabatine MS et al. N Engl J Med 2017; 376:1713-1722 2. Hines D et al. ACC 2017 abstract #1203-313 5

Background RNAi is an intrinsic process for inhibiting mRNA Synthetic siRNA dicer dsRNA Cleavage Natural process of RNA interference Strand separation RISC Complementary pairing Targeted gene silencing mRNA Cleavage mRNA degradation 6

Background GalNAc-siRNA conjugates facilitate rapid hepatic uptake Asialoglycoprotein receptor (ASGPR) GalNAc-siRNA inclisiran conjugate • Highly expressed in hepatocytes only • High rate of uptake Clathrin-coated pit ASGPR (pH>5) GalNAc 3 Recycling ASGPR Inclisiran • siRNA conjugated to N-acetylgalactosamine • Subcutaneous administration • Targeted delivery to hepatocytes 7

Methods ORION 1 trial design Screened (696) Stratified by country and Rx Randomized One dose start Two dose start (501) Placebo 200 mg 300 mg 500 mg Placebo 100 mg 200 mg 300 mg Treated (497) N=65 N=60 N=61* N=65* N=62 N=61* N=62* N=61 Day 1 Study drug given Day 1 Study drug given 1 st follow-up visit 1 st follow-up visit Day 14 Day 14 Day 30 Monthly follow-up visits Day 30 Monthly follow-up visits Day 90 Day 90 Study drug given Day 180 Primary evaluation Day 180 Primary evaluation Day 210 End of study visit Day 210 End of study visit Completed (483) Day 360 Extended follow-up Day 360 Extended follow-up 8

Patients High-risk CV patients, balanced by randomization One dose starting regimen Two dose starting regimen Placebo Inclisiran Placebo Inclisiran N=65 N=186 N=62 N=184 Age 62 63 63 64 Mean years Male sex 64.6 67.7 53.2 66.3 % Prior ASCVD 69.2 67.9 74.2 68.3 % Statin Rx 70.3 74.4 77.0 70.2 % LDL-C 128.5 125.9 125.2 133.0 Mean mg/dL Non-HDL-C 157.8 156.5 157.1 165.6 Mean mg/dL Apo-B 102.4 103.2 104.6 107.7 Mean mg/dL Lipoprotein(a) Median nmol/L 27.0 34.0 50.5 40.0 PCSK9 404.7 428.7 431.3 416.2 Mean ng/mL 9

Safety No safety concerns in study with follow up to Day 360 Similar overall adverse event profile and incidence for inclisiran and placebo No LFT elevations considered related to investigational drug • Similar incidence of transient transaminase increases in randomized groups No difference in incidence of myalgias or CPK enzyme elevation • One clinically relevant case of myonecrosis on placebo No deaths related to drug administration • Two previously reported deaths 1 >100 days, related to underlying disease 1: Patient A: History of CHD, MI and PCI died of a fatal MI on Day 104 of the study. (500mg x1 dose) Patient B: Developed complications of aortic aneurysm surgery including an aorto-esophageal fistula requiring esophagectomy, leading to infection of the prosthesis, sepsis, and stroke, culminating in death on Day 198 of the study. Patient also had AF, chronic renal failure, emphysema, HT and obesity. (200mg x2 doses) 10

Efficacy: One dose starting regimen Robust, sustained LDL-C reductions – 300 mg optimal 300mg 300 mg 300 mg 50.9% reduction 38.6% reduction 19.0% reduction 10 Mean percent change ( ± 95% CI) 0 Placebo -10 200mg P-value for all comparisons to placebo <0.0001 -20 300 mg -30 500 mg -40 -50 -60 0 30 60 90 120 150 180 210 240 270 300 330 360 Days from first injection 11

Efficacy: Two dose starting regimen Robust, sustained LDL-C reductions – optimal start regimen 300 mg x2 300 mg x2 55.5% 52.5% 31.4% Mean percent change ( ± 95% CI) 10 0 Placebo -10 100 mg P-value for all comparisons to placebo <0.0001 -20 200 mg -30 300 mg -40 -50 -60 0 30 60 90 120 150 180 210 240 270 300 330 360 Days from first injection 12

Sustained LDL-C lowering effects over time Time-averaged reduction from Day 1 to Day 360 One dose starting regimen Two dose starting regimen Time adjusted percent change Inclisiran Inclisiran Inclisiran Inclisiran Inclisiran Inclisiran 200 mg 300 mg 500 mg 100 mg 200 mg 300 mg in LDL-C to Day 360 -30% -30% -37% -39% -40% -46% 13

Inclisiran dose 300mg sc Day 1, 90, 270 and 6-monthly Sustained >50% reduction in LDL-C for 6-months One dose starting regimen (300 mg) Two dose starting regimen (300 mg) % Change in LDL-C from Baseline 10 10 Time adjusted LDL-C Time adjusted LDL-C 0 0 for 6 months = 41% for 6 months = 51% -10 -10 -20 -20 -30 -30 Q3 Q3 -40 -40 Mean Mean Median -50 -50 Median -60 -60 Q1 Q1 -70 -70 -80 -80 Day 90 Day 270 Day 90 Day 270 14

Efficacy: Day 360 LDL-C reduction in mg/dL Individual patient responses One dose starting regimen (N = 112) Two dose starting regimen (N = 142) 200 mg 300mg 500 mg 100 mg 200 mg 300 mg N = 38 N = 30 N = 44 N = 41 N = 48 N = 53 40 40 0 0 -40 -40 -80 -80 -120 -120 -160 -160 -200 -200 15

Conclusions Robust LDL-C  with 6 monthly inclisiran dosing Safety • By day 360, patients are predictably returning towards baseline • No safety signals at 1 year (>250 patient-years of observation) Dose and dose frequency • 300 mg given s.c. at Day 1 and Day 90 represents the optimal starting dose • 300 mg given s.c. at Day 270 then every 180 days is the maintenance dose This dosing schedule provides robust and consistent LDL-C lowering • 46% time-averaged reduction over 12 months • 51% time-averaged reduction over 6-monthly dosing interval • Minimal within-patient variability in LDL-C reduction over time 16

Implications Inclisiran has moved into Phase III LDL-C lowering trials underway • 3,000 subjects with ASCVD/ risk equivalents (ORION-10, -11) • 400 subjects with HeFH (ORION-9) • 60 subjects with HoFH (ORION-5) Parallel cardiovascular outcomes trial in preparation • 15,000 subjects with high risk ASCVD (ORION-4) 17

Backup

Safety No safety concerns in follow up to Day 360 Safety population One dose starting regimen Two dose starting regimen Placebo Inclisiran Placebo Inclisiran N=65 N=186 N=62 N=184 n (%) n (%) n (%) n (%) Any TEAE 51 (78.5) 155 (81.3) 51 (82.3) 153 (83.2) Serious 3 (4.6) 30 (16.1) 7 (11.3) 31 (16.8) Severe 2 (3.1) 18 (9.7) 7 (11.3) 22 (12.0) Related 12 (18.5) 39 (21.0) 19 (30.6) 52 (28.3) AE discontinuation 0 0 1 (1.6) 1 (0.5) Injection site reaction 0 7 (3.8) 0 12 (6.5) TEAEs (treatment emergent adverse events) - similar incidence placebo vs inclisiran: One dose starting regimen: Nasopharyngitis, myalgia, back pain, cough, arthralgia, headache Two dose starting regimen: Myalgia, headache, diarrhea, nasopharyngitis, arthralgia, back pain 19